newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Three Upcoming Investor Conferences

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced its management will participate in three upcoming investor conferences.
  • The company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25 at 9:20 am EST.
  • A fireside chat is scheduled for the TD Cowen 46th Annual Health Care Conference on March 4 at 9:50 am EST.
  • One-on-one meetings are planned for the Jefferies Biotech on the Beach Summit on March 10 & 11.
  • Webcasts for the Oppenheimer presentation & TD Cowen fireside chat will be available via the Investor Relations Events page on the company website.
  • Olverembatinib is the lead asset & the first novel third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations or resistance to prior TKIs.
  • All Olverembatinib indications are covered by the China National Reimbursement Drug List (NRDL).
  • The company is conducting the FDA-cleared global registrational Phase III POLARIS-2 trial for Olverembatinib in CML, plus Phase III trials for Ph+ ALL & SDH-deficient GIST.
  • Lisaftoclax is the company's second approved product, a Bcl-2 inhibitor for CLL/SLL patients who previously received BTK inhibitors.
  • Four global registrational Phase III trials are ongoing for Lisaftoclax: GLORA (combination with BTK inhibitors), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (newly diagnosed AML), & GLORA-4 (newly diagnosed HR MDS).
  • The GLORA-4 study received simultaneous clearance from the U.S. FDA, EU EMA, & China CDE.
  • The company holds global intellectual property rights & has partnerships with Takeda, AstraZeneca, Merck, Pfizer, & Innovent.
  • Ascentage Pharma maintains R&D relationships with institutions including Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, & University of Michigan.